Arjun Vasant Balar

13.3k total citations · 5 hit papers
144 papers, 4.6k citations indexed

About

Arjun Vasant Balar is a scholar working on Surgery, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Arjun Vasant Balar has authored 144 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 119 papers in Surgery, 92 papers in Oncology and 27 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Arjun Vasant Balar's work include Bladder and Urothelial Cancer Treatments (119 papers), Cancer Immunotherapy and Biomarkers (83 papers) and Urinary and Genital Oncology Studies (62 papers). Arjun Vasant Balar is often cited by papers focused on Bladder and Urothelial Cancer Treatments (119 papers), Cancer Immunotherapy and Biomarkers (83 papers) and Urinary and Genital Oncology Studies (62 papers). Arjun Vasant Balar collaborates with scholars based in United States, France and Netherlands. Arjun Vasant Balar's co-authors include Petros Grivas, Dean F. Bajorin, Peter H. O’Donnell, Noah M. Hahn, Jeffrey S. Weber, Ronald de Wit, Elizabeth R. Plimack, Joaquim Bellmunt, Daniel Castellano and Jacqueline Vuky and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Arjun Vasant Balar

135 papers receiving 4.6k citations

Hit Papers

First-line pembrolizumab in cisplatin-ineligible patients... 2017 2026 2020 2023 2017 2019 2021 2021 2021 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    2017 939 citations Arjun Vasant Balar, Daniel Castellano et al. The Lancet Oncology profile →
  2. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
    2019 435 citations Jonathan E. Rosenberg, Peter H. O’Donnell et al. profile →
  3. TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
    2021 351 citations Scott T. Tagawa, Arjun Vasant Balar et al. profile →
  4. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
    2021 329 citations Arjun Vasant Balar, Ashish M. Kamat et al. The Lancet Oncology profile →
  5. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial
    2021 175 citations Evan Y. Yu, Daniel P. Petrylak et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Arjun Vasant Balar United States 28 3.1k 2.7k 916 821 562 144 4.6k
Andrea B. Apolo United States 35 2.0k 0.6× 2.1k 0.8× 1.5k 1.6× 874 1.1× 491 0.9× 194 4.2k
Thomas Powles United Kingdom 24 1.9k 0.6× 2.4k 0.9× 1.1k 1.2× 649 0.8× 558 1.0× 105 3.7k
Christian Poehlein United States 22 1.6k 0.5× 2.7k 1.0× 1.2k 1.3× 559 0.7× 1.1k 2.0× 79 3.8k
Bradley A. McGregor United States 27 1.2k 0.4× 1.8k 0.7× 1.4k 1.5× 782 1.0× 270 0.5× 176 3.2k
Terence W. Friedlander United States 25 1.2k 0.4× 1.9k 0.7× 856 0.9× 678 0.8× 655 1.2× 112 3.1k
Annamaria H. Zimmermann United States 18 1.6k 0.5× 2.0k 0.7× 1.6k 1.7× 574 0.7× 135 0.2× 60 3.6k
Johnny Kao United States 31 827 0.3× 1.0k 0.4× 1.2k 1.3× 435 0.5× 580 1.0× 76 2.9k
Christopher J. VandenBussche United States 27 1.2k 0.4× 770 0.3× 262 0.3× 274 0.3× 163 0.3× 124 2.2k
Benedicte Parm Ulhøi Denmark 27 800 0.3× 511 0.2× 445 0.5× 856 1.0× 243 0.4× 66 2.1k
Daniele Raggi Italy 26 1.5k 0.5× 596 0.2× 540 0.6× 352 0.4× 93 0.2× 177 2.0k

Countries citing papers authored by Arjun Vasant Balar

Since Specialization
Citations

This map shows the geographic impact of Arjun Vasant Balar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arjun Vasant Balar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arjun Vasant Balar more than expected).

Fields of papers citing papers by Arjun Vasant Balar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arjun Vasant Balar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arjun Vasant Balar. The network helps show where Arjun Vasant Balar may publish in the future.

Co-authorship network of co-authors of Arjun Vasant Balar

This figure shows the co-authorship network connecting the top 25 collaborators of Arjun Vasant Balar. A scholar is included among the top collaborators of Arjun Vasant Balar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arjun Vasant Balar. Arjun Vasant Balar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Casciola‐Rosen, Livia, Arjun Vasant Balar, Ami A. Shah, et al.. (2025). Anti-cytolethal distending toxin antibodies in systemic sclerosis: associations with gastrointestinal disease and immune dysregulation. Lara D. Veeken. 64(12). 6349–6353.
2.
Loriot, Yohann, Arash Rezazadeh Kalebasty, Aude Fléchon, et al.. (2024). A plain language summary of the TROPHY-U-01 study: sacituzumab govitecan use in people with locally advanced or metastatic urothelial cancer. Future Oncology. 20(23). 1621–1631. 1 indexed citations
3.
Agarwal, Neeraj, Daniel Castellano, Teresa Alonso‐Gordoa, et al.. (2024). A Signal-Finding Study of Abemaciclib in Heavily Pretreated Patients with Metastatic Castration–Resistant Prostate Cancer: Results from CYCLONE 1. Clinical Cancer Research. 30(11). 2377–2383. 6 indexed citations
4.
Tannir, Nizar M., Adi Diab, Mario Sznol, et al.. (2022). Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study. Journal for ImmunoTherapy of Cancer. 10(4). e004419–e004419. 21 indexed citations
5.
Balar, Arjun Vasant, Daniel Castellano, Petros Grivas, et al.. (2022). Efficacy and safety of pembrolizumab in metastatic urothelial carcinoma: results from KEYNOTE-045 and KEYNOTE-052 after up to 5 years of follow-up. Annals of Oncology. 34(3). 289–299. 65 indexed citations
6.
7.
Balar, Arjun Vasant, Ashish M. Kamat, Girish S. Kulkarni, et al.. (2021). Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. The Lancet Oncology. 22(7). 919–930. 329 indexed citations breakdown →
8.
Richard, Guilhem, Anne S. De Groot, Gary D. Steinberg, et al.. (2021). Multi-step screening of neoantigens’ HLA- and TCR-interfaces improves prediction of survival. Scientific Reports. 11(1). 9983–9983. 6 indexed citations
9.
Loriot, Yohann, Arjun Vasant Balar, Daniel P. Petrylak, et al.. (2020). LBA24 TROPHY-U-01 cohort 1 final results: A phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). Annals of Oncology. 31. S1156–S1156. 19 indexed citations
10.
Grivas, Petros, Arjun Vasant Balar, Jacqueline Vuky, et al.. (2020). 744P Association between gene expression signatures (sigs) and pembrolizumab (pembro) efficacy in patients (pts) with advanced urothelial cancer (UC). Annals of Oncology. 31. S577–S578. 2 indexed citations
11.
O’Donnell, Peter H., Matthew D. Galsky, Jonathan E. Rosenberg, et al.. (2020). 746P EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors. Annals of Oncology. 31. S579–S580. 10 indexed citations
12.
Madison, Russell W., Douglas I. Lin, Alexa B. Schrock, et al.. (2020). Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA. Oncology. 98(12). 905–912. 36 indexed citations
13.
Grivas, Petros, Elizabeth R. Plimack, Arjun Vasant Balar, et al.. (2020). Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. European Urology Oncology. 3(3). 351–359. 33 indexed citations
14.
Donnelly, Douglas M., Shirin Bajaj, Arjun Vasant Balar, et al.. (2019). The complex relationship between body mass index and response to immune checkpoint inhibition in metastatic melanoma patients. Journal for ImmunoTherapy of Cancer. 7(1). 222–222. 76 indexed citations
15.
Xia, Yuhe, et al.. (2019). Outcomes With First-line PD-1/PD-L1 Inhibition in Advanced Urothelial Cancer: A Single Institution Experience. Clinical Genitourinary Cancer. 18(3). e209–e216. 2 indexed citations
16.
Lattanzi, Michael, Fang‐Ming Deng, Luis Chiriboga, et al.. (2018). Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. Journal for ImmunoTherapy of Cancer. 6(1). 97–97. 22 indexed citations
17.
Balar, Arjun Vasant & Jeffrey S. Weber. (2017). PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunology Immunotherapy. 66(5). 551–564. 230 indexed citations
18.
Bellmunt, Joaquim, Arjun Vasant Balar, Matthew D. Galsky, et al.. (2016). IMvigor210: updated analyses of first-line (1L) atezolizumab (atezo) in cisplatin (cis)-ineligible locally advanced/metastatic urothelial carcinoma (mUC). Annals of Oncology. 27. vi270–vi270. 10 indexed citations
19.
Balar, Arjun Vasant, Joaquim Bellmunt, Peter H. O’Donnell, et al.. (2016). Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: Preliminary results from the phase 2 KEYNOTE-052 study. Annals of Oncology. 27. vi567–vi567. 49 indexed citations
20.
Kang, Stella K., Alexander Volodarskiy, Erin Ohmann, Arjun Vasant Balar, & Sripal Bangalore. (2015). Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials. Clinical Oncology. 28(5). 334–341. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea B. Apolo Breakdown of academic impact, for papers by Thomas Powles Breakdown of academic impact, for papers by Christian Poehlein Breakdown of academic impact, for papers by Bradley A. McGregor Breakdown of academic impact, for papers by Terence W. Friedlander Breakdown of academic impact, for papers by Annamaria H. Zimmermann Breakdown of academic impact, for papers by Johnny Kao Breakdown of academic impact, for papers by Christopher J. VandenBussche Breakdown of academic impact, for papers by Benedicte Parm Ulhøi Breakdown of academic impact, for papers by Daniele Raggi
Rankless by CCL
2026